2021 DORIS definition of remission in SLE: final recommendations from an international task force.

Authors
van Vollenhoven, Ronald F  ORCID logo  https://orcid.org/0000-0001-6438-8663
Bertsias, George 
Isenberg, David 

Change log
Abstract

OBJECTIVE: To achieve consensus on a definition of remission in SLE (DORIS). BACKGROUND: Remission is the stated goal for both patient and caregiver, but consensus on a definition of remission has been lacking. Previously, an international task force consisting of patient representatives and medical specialists published a framework for such a definition, without reaching a final recommendation. METHODS: Several systematic literature reviews were performed and specific research questions examined in suitably chosen data sets. The findings were discussed, reformulated as recommendations and voted on. RESULTS: Based on data from the literature and several SLE-specific data sets, a set of recommendations was endorsed. Ultimately, the DORIS Task Force recommended a single definition of remission in SLE, based on clinical systemic lupus erythematosus disease activitiy index (SLEDAI)=0, Evaluator's Global Assessment <0.5 (0-3), prednisolone 5 mg/day or less, and stable antimalarials, immunosuppressives, and biologics. CONCLUSION: The 2021 DORIS definition of remission in SLE is recommended for use in clinical care, education, and research including clinical trials and observational studies.

Publication Date
2021-11
Online Publication Date
2021-11-24
Acceptance Date
2021-11-04
Keywords
healthcare, lupus erythematosus, outcome assessment, systemic, therapeutics, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Prednisolone, Remission Induction, Severity of Illness Index
Journal Title
Lupus Sci Med
Journal ISSN
2053-8790
2053-8790
Volume Title
8
Publisher
BMJ
Sponsorship
UCB Pharma (n/a)
GlaxoSmithKline (n/a)